Pre-made Ivuxolimab benchmark antibody ( Whole mAb, anti-TNFRSF4/CD134 therapeutic antibody, Anti-ACT35/IMD16/OX40/TXGP1L Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-285

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-285 Category Tag

Product Details

Pre-Made Ivuxolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ivuxolimab (also known as PF 4518600 or PF 8600) is an OX40 receptor agonist, as an intravenous therapy for solid tumours is in development with Pfizer.

Products Name (INN Index)

Pre-Made Ivuxolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody

INN Name

Ivuxolimab

Target

TNFRSF4

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG2

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2019

Companies

Pfizer,Dana-Farber Cancer Institute,M. D. Anderson Cancer Center,National Cancer Institute USA,University of Southern California

Conditions Approved

NA

Conditions Active

Breast cancer,Renal cell carcinoma,Solid tumours,Acute myeloid leukaemia,Squamous cell cancer,Follicular lymphoma

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

TNFRSF4

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide